The global bio-implant market size was estimated at USD 65.0 billion in 2018 and will exhibit a CAGR of 5.9% during the forecast period. Rising adoption of bio-implant procedures, over arthroscopy and other therapy treatments such as physiotherapy, is a major factor driving the market. This preference is attributed to associated benefits such as higher success rate and biocompatibility. Other factors propelling the market include increasing prevalence of cardiovascular diseases (CVD) and orthopedic ailments, large geriatric population base, lifestyle changes, and rising adoption of cosmetic surgeries.
The market is also driven by rising awareness about cosmetic implants and advancements in bioengineering technologies. Demand for non-surgical or minimally invasive bio-implants is growing in numerous medical disciplines. For instance, an increasing number of dental patients are choosing to opt for bio-implants as an easier and more effective alternative to a root canal procedure. Alarming increase in oral healthcare problems will further stimulate demand for bio-implants. For instance, WHO’s 2016 Global Burden of Disease Study (GBDS) estimated that oral diseases affected around half of the population worldwide. Almost 3.58 billion people were known to be affected by dental caries and various tooth problems. This will provide a wider addressable market in the near future.
Sedentary lifestyle has been the root cause of numerous chronic disorders such as CVD, congenital and neuropathic disorders, and osteoarthritis. This has propelled the demand for bio-implants across the globe. For instance, according to the National Spinal Cord Injury Statistical Center, almost 54.0% of the population in the U.S. was suffering from spinal cord injury in 2016. These incidences are expected to affect almost 60% of the U.S. population by 2020, resulting in growth opportunities for the market.
Technological advancements in manufacturing of bio-implants, such as 3D printing, laser technology, and nanotechnology, have significantly enhanced the biocompatibility of these products. These efforts are strongly supported by rise in healthcare funding by governments around the world. A number of government bodies are teaming up with healthcare research and manufacturing companies to bring innovative and more effective devices to the market. For instance, in June 2019, the Government of Kazakhstan expressed its interest in joining forces with MIDHANI, an Indian bio-implant manufacturer, to produce titanium bio-implants on a commercial scale.
Based on product, orthopedic implants accounted for the leading share in 2018. This can be attributed to factors such as rising adoption of implants in orthopedic surgeries, rising incidence of orthopedic diseases, and favorable reimbursement policies by various governments. According to the Centers for Disease Control and Prevention (CDC), in 2017, almost 54.4 million adults were suffering from arthritis in U.S. alone.
On the other hand, dental implants are expected to grow at a higher rate during the forecast period due to factors such as ageing population with more tooth deformities and increasing demand for dental and cosmetic surgeries. The American Academy of Implant Dentistry estimated in 2017 that more than 69.0% of Americans of between 35 and 44 years of age have one missing tooth. Moreover, sedentary lifestyle and increasing consumption of tobacco and nicotine are also expected to increase dental issues in the coming years. This will have an overall impact on demand for bio-implants in the dental category.
Based on material, the biomaterial metal segment commanded the largest share in the bio-implant market in 2018 and is expected to maintain its position over the forecast period. Associated advantages such as higher tensile strength, coupled with resistance to corrosion as compared to other materials like ceramics and alloys, are major growth drivers for this segment. Applications of biomaterial metals include dental implants, joint replacement implants, and pacemaker cases.
On the other hand, ceramic implants are expected to grow at a significant rate during the forecast period. Ceramics have been garnering much interest mainly because of their ability to deliver a necessary mechanical function for tissue reconstruction. Furthermore, bio-ceramics, with their additional capability of stimulating bone regeneration tissues, are anticipated to gain faster adoption in the coming years.
On the basis of origin, xenografts commanded the leading market share in 2018, majorly due to their biological origin, which makes them more compatible with the human body. On the other hand, allografts are expected to grow at a higher rate during the forecast period. This is attributed to benefits such as lower risk of harvest site morbidity, reduced postoperative pain, as well as shorter surgical and recovery time. According to insights by LifeLink Tissue Bank in 2018, over 1.7 million allografts are implanted each year in the U.S. These grafts are employed in almost all surgical disciplines, such as orthopedic, gynecology, cardiac surgery, and neurology.
Based on end use, the market is segmented into hospitals, clinics, and specialty centers. Hospitals held the dominant share in the market in 2018 and will retain its lead throughout the forecast period. This can be attributed to large patient footfall and favorable reimbursement policies for costly implants, such as pacemakers, in government hospitals. Clinics accounted for the second largest revenue share in 2018 and will exhibit steady growth through 2026.
However, in recent years, there has been growing inclination for specialty centers when it comes to treatment of various cardiac and orthopedic diseases. This can be attributed to rising awareness about different conditions and their treatment options as well as increasing disposable income. These specialized centers contribute to the goal of better clinical outcomes at reduced costs, as these settings are suited to match precise medical conditions. These factors are expected to propel the growth of the segment during the forecast period.
North America is anticipated to dominate the global market owing to factors such as increasing number of surgical procedures needing implants and rising adoption of advanced technologies across various medical disciplines.According to the Organisation for Economic Co-operation and Development (OECD) Health Statistics, more than 1.4 million orthopedic procedures were conducted in 2017, including hip and knee replacement surgeries, which is poised to grow in the near future. This is likely to benefit regional growth.
Europe is the second largest market for bio-implants, fueled by government funding and support, rising incidence of orthopedic disorders, and growing R&D activities. For instance, many pacemaker manufacturers are working on developing MRI-conditional and leadless pacemakers. Furthermore, increasing number of CVD surgeries, on the heels of rising prevalence of the condition, is propelling market growth.
Asia Pacific is projected to be the fastest-growing market over the forecast period, primarily owing to high incidence of spinal cord injuries. This can be attributed to an alarming occurrence of road accidents. According to Tokyo’s Keio University’s 2019 publication, more than 100,000 patients in Japan are paralyzed due to spinal cord injuries. However, recent approval of iPS technology in the country is expected to help such patients in the coming years, leading to new market opportunity for bio-implants.
Increasing number of acquisitions and mergers, rising number of partnerships and collaborations, new product launches, and growing research and development activities are some of the key trends observed in the global market. For instance, in March 2018, Orthofix International N.V. acquired Spinal Kinetics Inc., a privately held manufacturer and developer of lumbar discs and artificial cervical. The move was aimed at strengthening Orthofix’s orthobiologics bio-implant product portfolio.
MaterialsCare’s 3D printing methods for bio-implants are currently solely dedicated for veterinarian use; however, the company has stated that the technology will be available for human use by the end of 2021. Similarly, technological advancements have created new opportunities for players in biomaterial development. For instance, LifeNet’s patented technology for allografts, Matracell, is currently used by most major players in market for bio-implants, including Stryker and Arthrex.
Leading companies operating in this market include Medtronic; St Jude Medical (Abbott); Stryker; DePuy Synthes; Zimmer Biomet; Organogenesis, Inc.; Arthrex, Inc.; Orthofix Holdings, Inc.; Cochlear Ltd.; and Exactech, Inc.
Report Attribute |
Details |
Market size value in 2020 |
USD 72,590.27 million |
Revenue forecast in 2026 |
USD 102,696.03 million |
Growth Rate |
CAGR of 5.9% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2014 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, material, origin, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; India; China; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; UAE |
Key companies profiled |
Medtronic; St Jude Medical (Abbott); Stryker; DePuy Synthes; Zimmer Biomet; Organogenesis, Inc.; Arthrex, Inc.; Orthofix Holdings, Inc.; Cochlear Ltd.; Exactech, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global bio-implant market report on the basis of product, material, origin, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Cardiovascular Implants
Pacing Devices
Pacemaker
ICDs
Stents
Orthopedic Implants
Orthobiologics
Trauma Implants
Hip Replacements
Knee Replacements
Spinal Implants
Dental Implants
Ophthalmic Implants
Others
Material Outlook (Revenue, USD Million, 2014 - 2026)
Ceramics
Polymers
Alloys
Biomaterial Metal
Origin Outlook (Revenue, USD Million, 2014 - 2026)
Autograft
Allograft
Xenograft
Synthetic
End-use Outlook (Revenue, USD Million, 2014 - 2026)
Hospitals
Clinics
Specialty Centers
Regional Outlook (Revenue, USD Million, 2014 - 2026)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
UAE
b. The global bio implant market size was estimated at USD 68,686.91 million in 2019 and is expected to reach USD 72,590.27 million in 2020.
b. The global bio implant market is expected to grow at a compound annual growth rate of 5.9% from 2019 to 2026 to reach USD 102,696.03 million by 2026.
b. North America dominated the bio implant market with a share of 33.50% in 2019. This is attributable to the increasing number of surgical procedures needing implants and rising adoption of advanced technologies across various medical disciplines.
b. Some key players operating in the bio implant market include Medtronic; St Jude Medical (Abbott); Stryker; DePuy Synthes; Zimmer Biomet; Organogenesis, Inc.; Arthrex, Inc.; Orthofix Holdings, Inc.; Cochlear Ltd.; and Exactech, Inc.
b. Key factors that are driving the bio implant market growth include increasing adoption of bio-implant procedures, over arthroscopy and other therapy treatments such as physiotherapy, prevalence of cardiovascular diseases (CVD) and orthopedic ailments, large geriatric population base, lifestyle changes, and rising adoption of cosmetic surgeries.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."